Published in Ann Endocrinol (Paris) on December 01, 2000
Factors for thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Ups J Med Sci (2009) 0.85
Helicobacter pylori infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis. Diabetol Metab Syndr (2011) 0.84
Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int (2006) 2.52
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med (2001) 1.75
Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations. Muscle Nerve (2004) 1.73
A systematic study of HLA class II-beta DNA restriction fragments in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1985) 1.69
Multitissular involvement in a family with LMNA and EMD mutations: Role of digenic mechanism? Neurology (2007) 1.59
Class II HLA-DC beta-chain DNA restriction fragments differentiate among HLA-DR2 individuals in insulin-dependent diabetes and multiple sclerosis. Proc Natl Acad Sci U S A (1984) 1.52
Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc Natl Acad Sci U S A (1996) 1.47
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Arch Cardiovasc Dis (2012) 1.42
Comparison of Tc-99m-labelled antileukocyte fragment Fab' and Tc-99m-HMPAO leukocyte scintigraphy in the diagnosis of bone and joint infections: a prospective study. Nucl Med Commun (2000) 1.41
[Oral manifestations of endocrine dysfunction]. Ann Endocrinol (Paris) (2004) 1.39
Technical risks with subcutaneous insulin infusion. Diabetes Metab (2006) 1.29
Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab (1990) 1.20
Anion selectivity by the sodium iodide symporter. Endocrinology (2003) 1.16
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (2013) 1.15
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) (2000) 1.15
Long-term culture of human pancreatic islets in an extracellular matrix: morphological and metabolic effects. Mol Cell Endocrinol (1993) 1.07
Insulin pump failures are still frequent: a prospective study over 6 years from 2001 to 2007. Diabetologia (2009) 1.03
HLA and Graves' disease: an association with HLA-DRw3. J Clin Endocrinol Metab (1980) 1.02
Vitamin D deficiency, vitamin D receptor gene polymorphisms and cardiovascular risk factors in Caribbean patients with type 2 diabetes. Diabetes Metab (2011) 1.02
Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) (1999) 0.98
Multicenter randomized evaluation of a nutritional education software in obese patients. Diabetes Metab (2001) 0.96
Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. Eur J Endocrinol (2011) 0.93
Specific activation of the thyrotropin receptor by trypsin. Mol Cell Endocrinol (1996) 0.93
Survey of CAG/CTG repeats in human cDNAs representing new genes: candidates for inherited neurological disorders. Hum Mol Genet (1996) 0.92
The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. J Clin Endocrinol Metab (2009) 0.91
Clinical and statistical evaluation of self-monitoring blood glucose meters. Diabetes Care (1998) 0.90
Association of class II HLA-DQ beta chain DNA restriction fragments with multiple sclerosis. Immunogenetics (1985) 0.90
Heterogeneity of diabetes phenotype in patients with 3243 bp mutation of mitochondrial DNA (Maternally Inherited Diabetes and Deafness or MIDD). Diabetes Metab (2004) 0.90
Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) (2001) 0.89
Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv Rev Fr Hematol (1995) 0.87
Rathke's cleft cysts: surgical-MRI correlation in 16 symptomatic cases. J Neuroradiol (1999) 0.85
Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease? Clin Endocrinol (Oxf) (1984) 0.85
Diagnosis of osteomyelitis in the diabetic foot with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99mTc-MDP bone scintigraphy. Diabetes Metab (2002) 0.84
Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab (2002) 0.84
Properdin factor B (Bf) and glyoxalase in Graves' disease. Acta Endocrinol (Copenh) (1983) 0.83
Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus. Metabolism (1996) 0.83
Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta (2006) 0.83
Sphingolipid-cholesterol domains (lipid rafts) in normal human and dog thyroid follicular cells are not involved in thyrotropin receptor signaling. Endocrinology (2003) 0.82
Anti-pancreatic autoimmunity and Graves' disease: study of a cohort of 600 Caucasian patients. Eur J Endocrinol (1997) 0.82
Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control. Diabetes Metab (2010) 0.82
Serum lysosomal acid hydrolase activities in Graves' disease. Clin Chim Acta (1982) 0.82
Kinetics of thyrotropin-stimulating hormone (TSH) and thyroid-stimulating antibody binding and action on the TSH receptor in intact TSH receptor-expressing CHO cells. J Clin Endocrinol Metab (2003) 0.82
[Nuclear medicine in the diagnosis of diabetic foot osteomyelitis]. Diabetes Metab (2001) 0.81
In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4,5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence. Eur J Biochem (1995) 0.81
Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism. Clin Pharmacol Ther (2010) 0.80
Assays for thyrotropin-receptor binding and thyroid-stimulating antibodies in sera from patients with Graves' disease. Clin Chem (1986) 0.80
[Primary adrenal lymphoma with latent adrenal insufficiency: a case report and literature review]. Ann Endocrinol (Paris) (1998) 0.80
Acrylamide, an in vivo thyroid carcinogenic agent, induces DNA damage in rat thyroid cell lines and primary cultures. Mol Cell Endocrinol (2006) 0.80
Species specific thyroid signal transduction: conserved physiology, divergent mechanisms. Mol Cell Endocrinol (2010) 0.80
[Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy]. Presse Med (1991) 0.79
[Inappropriate secretion of antidiuretic hormone and diabetes insipidus after surgery for pituitary adenoma]. Ann Endocrinol (Paris) (2003) 0.79
Identification of a novel mutation (A268G) in exon 8 of the HTR beta gene in a large family with thyroid hormone resistance. Hum Mutat (1996) 0.79
The orphan receptor cDNA RDC4 encodes a 5-HT1D serotonin receptor. Biochem Biophys Res Commun (1991) 0.79
[Prevalence of hypertension in a black African diabetic population]. Arch Mal Coeur Vaiss (1996) 0.79
The human and dog 5-HT1D receptors can both activate and inhibit adenylate cyclase in transfected cells. Eur J Pharmacol (1993) 0.78
Determination of serum insulin-like growth factor-I reference values for the automated chemiluminescent Liaison® assay. Clinical utility in the follow-up of patients with treated acromegaly. Clin Chim Acta (2010) 0.77
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab (2011) 0.77
Contribution of technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy to the diagnosis of diabetic foot infection. Eur J Nucl Med (1998) 0.77
Comparative effects of 6 week fructose, dextrose and starch feeding on fat-cell lipolysis in normal rats: effects of isoproterenol, theophylline and insulin. Mol Cell Biochem (1992) 0.77
A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype. J Clin Endocrinol Metab (1983) 0.77
[Value of the urinary albumin/creatinine ratio in the detection of microalbuminuria]. Presse Med (1988) 0.77
Increased serum ferritin in insulin-dependent diabetes mellitus: relation to glycemic control. Clin Chem (1994) 0.76
[Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies)]. Ann Dermatol Venereol (2005) 0.76
Determination of serum insulin-like growth factor-I reference values for the immunometric Cisbio method on a large number of healthy subjects: clinical utility in the follow-up of patients with treated acromegaly. Clin Chim Acta (2007) 0.76
Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest (1999) 0.76
Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients. Diabetes Metab (2000) 0.76
[Graves' disease. Predominance of the DRw3 antigen (author's transl)]. Nouv Presse Med (1980) 0.76
[Thyroid hormone analogs: an important biological supply and new therapeutic possibilities]. Ann Endocrinol (Paris) (2008) 0.76
Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease. BMJ (1989) 0.75
H2O2, signal, substrate, mutagen and chemorepellent from physiology to biochemistry and disease. Bull Mem Acad R Med Belg (2010) 0.75
[Changes in serum levels of angiotensin converting enzyme in Basedow's disease]. Presse Med (1986) 0.75
[Proposed reference values for nine methods for measurement of free thyroxin]. Ann Biol Clin (Paris) (2004) 0.75
[HLA DRW3 and Graves' disease (author's transl)]. Ann Endocrinol (Paris) (1980) 0.75
[Recommendations for the standardization of growth hormone assays]. Ann Biol Clin (Paris) (2004) 0.75
[Gastric bypass in the treatment of major obesity. 15 cases]. Presse Med (1984) 0.75
[Cushing's disease caused by probable pituitary microadenoma associated with an intrasellar arachnoidal diverticulum]. Presse Med (1985) 0.75
[HL-A system and Graves' disease. Predominance of the DRW3 antigen]. Rev Med Interne (1980) 0.75
[Ketoacidosis during ambulatory treatment by continuous subcutaneous infusion of insulin. Possible role of catheter infection]. Presse Med (1984) 0.75
[Primary hyperprolactinemia associated with von Recklinghausen's neurofibromatosis]. Presse Med (1984) 0.75
[Polyneuritis due to nitrofuran derivatives]. Sem Hop (1975) 0.75
Mutation analysis of the Epac--Rap1 signaling pathway in cold thyroid follicular adenomas. Eur J Endocrinol (2001) 0.75
[Accidents attributable to carbimazole in the treatment of Basedow's disease]. Ann Endocrinol (Paris) (1984) 0.75
[Hypocalcaemia in a patient presenting severe solar urticaria]. Ann Dermatol Venereol (2008) 0.75
[Ovarian hyperstimulation induced by the pulsatile administration of gonadoliberin]. Presse Med (1984) 0.75
[Should hot quenching subtoxic thyroid nodules be surgically treated systematically?]. Presse Med (1984) 0.75
[Hyperthyroidism after intravenous urography]. Nouv Presse Med (1976) 0.75